Skip to main
QURE

uniQure (QURE) Stock Forecast & Price Target

uniQure (QURE) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 50%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

uniQure NV has demonstrated a commitment to advancing its pipeline of gene therapies, particularly through positive data and supportive feedback regarding its lead product, AMT-130, which management asserts holds a compelling efficacy profile for Huntington's disease. The company's strategic collaboration with Bristol Myers Squibb in developing treatments for cardiovascular diseases further solidifies its growth potential in significant markets. Additionally, encouraging developments in other trials, such as the Phase 1/2a GenTLE trial for AMT-260 in mesial temporal lobe epilepsy, coupled with a favorable regulatory environment, underscore a robust outlook for the company's future financial performance.

Bears say

The analysis indicates a negative outlook for uniQure NV due to significant regulatory and developmental delays concerning its gene therapy, AMT-130, which could hinder future revenue generation as management has withdrawn prior guidance for a pivotal submission timeline. The company continues to face financial risks as it remains in the clinical stage without any market-ready products, resulting in cumulative losses since its inception. Additionally, increased competition from both existing and emerging therapies targeting similar indications poses a risk to its potential market penetration and pricing strategy.

uniQure (QURE) has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 50% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About uniQure (QURE) Forecast

Analysts have given uniQure (QURE) a Buy based on their latest research and market trends.

According to 10 analysts, uniQure (QURE) has a Buy consensus rating as of Jan 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $57.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $57.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

uniQure (QURE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.